Perrigo

Perrigo Co. Plc engages in the provision of self-care products and over-the-counter (OTC) health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the following segments: Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The CSCI segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Perrigo reports strong Q1 growth, faces challenges in product shortages

Perrigo's Q1 2023 performance showcased growth and margin expansion, with a focus on operational excellence. The company faces challenges with product shortages and declining national brand volumes but sees opportunities in pricing increases and supply chain optimization. By leveraging strengths in private label growth and strategic initiatives, Perrigo aims to deliver on guidance for the year.

Perrigo reports strong Q2 performance, eyes Opill launch success

Perrigo's Q2 2023 earnings call highlighted strong financial performance, strategic strengths, key challenges, and growth opportunities. The company is focused on sustainable growth, market differentiation, and leveraging its capabilities for success in the industry.

Perrigo reports solid Q3 earnings, navigates challenges for future growth

Perrigo's Q3 performance showcased growth in net sales and margin expansion, despite challenges in certain product segments. The company remains focused on margin improvement, supply chain optimization, and growth initiatives for future success. With revised outlooks and ongoing strategic efforts, Perrigo aims to navigate challenges and capitalize on growth opportunities.

Perrigo reports robust Q4 earnings, focuses on growth initiatives

Perrigo's Q4 2023 earnings call showcased strong financial performance, with notable growth in net sales and margins.
While facing challenges in its infant formula business, the company outlined remediation plans and expects recovery in the second half of 2024.
Opportunities lie in the launch of Opill, Project Energise, and a focus on strengthening the infant formula business.
Perrigo aims to drive growth by executing strategic initiatives and providing more clarity on growth perspectives during an upcoming Investor Day.

Perrigo reports Q1 challenges, Opill success, and growth opportunities

Perrigo faced challenges in net sales due to infant formula actions but showed strength in innovation and store brands.
Opportunities lie in adapting to retailer inventory changes and expected gross margin improvement in Q2.
The company remains on track to meet 2024 commitments with progress in infant formula recovery and successful product launches.
Analysts focused on infant formula progress, Opill revenue potential, and portfolio refinements during the call.

Perrigo reports Q2 resilience amidst challenges, eyes growth opportunities

Perrigo faced challenges in Q2 2024 with a decline in organic net sales, primarily due to infant formula and certain category sales. Despite this, the company showed resilience with growth in operating income and a focus on core segments. Opportunities lie in recovering share, enhancing marketing, and the potential for infant formula recovery.

Perrigo reports robust Q3 earnings, focuses on efficiency and growth

Perrigo's Q3 performance reflects a resilient financial position, marked by strong EPS growth and operational efficiency gains through cost-saving initiatives.
While facing challenges in net sales decline, the company's strategic focus on core business stabilization and efficiency improvements bodes well for long-term growth.
With a commitment to financial targets, Perrigo is poised to capitalize on opportunities for revenue diversification and market expansion, supported by a strengthened operational foundation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perrigo Co. Plc engages in the provision of self-care products and over the counter health and wellness solutions. It enhances individual well-being by empowering consumers to proactively prevent or treat conditions that can be self-managed. It operates through the Consumer Self-Care Americas and Consumer Self-Care International segments. The Consumer Self-Care Americas segment offers OTC solutions, infant formula, oral care, and contract manufacturing in the U.S, Mexico, and Canada. The Consumer Self-Care International segment includes the self-care business branded in Europe, Australia, the United Kingdom, and parts of Europe and Asia. The company was founded by Luther Perrigo in 1887 and is headquartered in Dublin, Ireland.

Investors responded positively to the drugmaker's sneak peek at its Q4 and full-year results.

Why Perrigo Shares Are Jumping Today

Shares of Perrigo Co. Plc PRGO, +8.47% rallied about 9% on Tuesday, after Leerink said sales guidance offered earlier in the day was strong.

Perrigo stock up 9% as Leerink says sales guidance was 'particularly strong'

Perrigo Co. Plc PRGO, +1.67% said Tuesday it expects 2019 sales to come to $4.8 billion, up 2% from the year-earlier period and ahead of the $3.98 billion FactSet consensus.

Perrigo shares jump 2.8% premarket after offering above-consensus sales guidance

Applied Materials

Coty, General Electric, Perrigo, Lennar, Applied Materials, Tyson Foods and other stocks that posted big losses in 2018 reversed course this year, and investing pros say some could continue winning in 2020.

Last year's worst stocks were some of 2019's best. Here are 2 pros' favorites

Perrigo (PRGO) reported earnings 30 days ago. What's next for the stock?

Perrigo (PRGO) Up 4.1% Since Last Earnings Report: Can It Continue?

Alteryx

3 Big Stock Charts for Thursday: Facebook, Perrigo, and Alteryx

Witi, a producer of medical-grade vaporization devices, announced Thursday it has partnered with Perrigo (NYSE: PRGO) to create a new smoking cessation product.

Witi, Perrigo Partner To Help Smokers Overcome Nicotine Addiction

Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2019 Results - Earnings Call Transcript

Perrigo (PRGO) reports mixed third-quarter 2019 results. The Rx segment continues to witness recovery.

Perrigo (PRGO) Beats on Q3 Earnings, Tightens '19 EPS View

Perrigo (PRGO) delivered earnings and revenue surprises of 11.83% and -0.95%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Beats Q3 Earnings Estimates

Spartan Motors

Three loyal dividend payers declared payments on Monday.

3 Loyal Dividend Payers Declare Distributions

Perrigo's (PRGO) Consumer Self Care Americas segment is expected to have aided the company's top line in the soon-to-be reported quarter.

What's in the Cards for Perrigo (PRGO) This Earnings Season?

Why Is Perrigo (PRGO) Up 6.1% Since Last Earnings Report?

Bio-Rad Laboratories

PRGO vs. BIO: Which Stock Is the Better Value Option?

Perrigo Company's (PRGO) CEO Murray Kessler on Q2 2019 Results - Earnings Call Transcript

Perrigo (PRGO) reports encouraging second-quarter 2019 results. The Rx segment recovers  on strong new product sales.

Perrigo (PRGO) Beats on Q2 Earnings and Sales, Stock Up

Perrigo (PRGO) delivered earnings and revenue surprises of 6.17% and 1.58%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Perrigo (PRGO) Tops Q2 Earnings and Revenue Estimates

Perrigo Co (NYSE: PRGO) reported second-quarter earnings of 86 cents per share, which beat the analyst consensus estimate of 79 cents by 8.86%.

Perrigo Reports Q2 Earnings, Reaffirms Guidance

Shares of Perrigo Co. PRGO, +0.10% surged 6.0% in premarket trading Thursday, after the over-the-counter health and wellness products company reported second-quarter profit and revenue that beat expectations, and affirmed its full-year outlook.

Perrigo's stock surges after profit and revenue decline less than expected, outlook affirmed

Surmodics

PRGO vs. SRDX: Which Stock Is the Better Value Option?

PRGO or SRDX: Which Is the Better Value Stock Right Now?

Shares of Dublin-based Perrigo Co. Plc rose 1.5% in premarket trade Wednesday after the company said the U.S. Food and Drug Administration had approved a development partner's marketing application for a generic version of Metrogel-Vaginal, a treatment for bacterial vaginosis.

Perrigo shares up 1.5% after FDA approves marketing application for generic antibacterial

Perrigo Company (NYSE: PRGO) has acquired Ranir Global Holdings, a supplier of oral self-care products for $750 million in cash.

Perrigo Adjusts Guidance After Acquiring Ranir Global For $750M

Shares of Perrigo Co. Plc rose 2% in premarket trade Tuesday after the company raised its adjusted full-year EPS guidance to between $3.75 and $4.05 from between $3.65 and $3.95.

Perrigo shares up 2% after company boosts adjusted full-year EPS guidance by 10 cents

Why Is Perrigo (PRGO) Down 17.4% Since Last Earnings Report?

Perrigo (PRGO) reports encouraging first-quarter 2019 results. The Rx segment recovers during the quarter on strong new product sales.

News for Perrigo Stock (PRGO)